Holen Sie sich die Stockscreener-App
14.87
2.43%
-0.37
Handel nachbörslich:
15.00
0.13
+0.87%
Schlusskurs vom Vortag:
$15.24
Offen:
$15.55
24-Stunden-Volumen:
1.66M
Relative Volume:
1.35
Marktkapitalisierung:
$465.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-2.6566
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
-7.06%
1M Leistung:
-43.78%
6M Leistung:
-57.29%
1J Leistung:
-43.55%
1-Tages-Spanne:
$14.84
$15.68
1-Wochen-Bereich:
$14.84
$17.51
52-Wochen-Spanne:
$14.84
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
14.87 | 476.86M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Will LENZ Therapeutics Inc. stock see insider buying2025 Volatility Report & Fast Moving Stock Watchlists - ulpravda.ru
LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch - VisionMonday.com
Can LENZ Therapeutics Inc. stock reach $100 price targetJuly 2025 Patterns & Real-Time Buy Signal Alerts - ulpravda.ru
How sustainable is LENZ Therapeutics Inc. stock dividend payoutJuly 2025 Opening Moves & Long Hold Capital Preservation Tips - ulpravda.ru
Why LENZ Therapeutics Inc. stock is recommended by analystsTrade Risk Assessment & Community Verified Trade Alerts - ulpravda.ru
Why LENZ Therapeutics Inc. stock could outperform in 2025Analyst Upgrade & Risk Controlled Stock Pick Alerts - ulpravda.ru
Why LENZ Therapeutics Inc. stock is popular among millennialsJuly 2025 Selloffs & Daily Oversold Bounce Ideas - ulpravda.ru
Analysts Expect Breakeven For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Before Long - Yahoo Finance
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates - The Manila Times
LENZ Therapeutics Reports Strong Initial Sales and Prescription Volume for VIZZ™ after Launch for Presbyopia Treatment - Quiver Quantitative
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ ... - Bluefield Daily Telegraph
Page not foundFactor Thisâ„¢ - FinancialContent
Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East - Yahoo Finance
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ in the Middle East - MarketScreener
LENZ Therapeutics and Lunatus Ink Exclusive Commercialization Partnership for VIZZ in Middle East - VisionMonday.com
Lenz Therapeutics and Lunatus announce partnership for Vizz(TM) - marketscreener.com
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East - The Manila Times
FDA-approved presbyopia eye drop VIZZ to reach Middle East - Stock Titan
LENZ Therapeutics responds to FDA adverse event report - MSN
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year LowWhat's Next? - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc.LENZ - PR Newswire
Is LENZ Therapeutics Inc a good long term investmentConsumer Goods Stocks & Free Stay Informed With Forecasts - earlytimes.in
Aug Mood: Why LENZ Therapeutics Inc stock is recommended by analystsQuarterly Profit Summary & Expert Approved Trade Ideas - moha.gov.vn
LENZ Therapeutics (LENZ) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 5.1%Time to Sell? - MarketBeat
Lenz plunges after adverse event report on eye therapy - MSN
How LENZ Therapeutics Inc. stock compares to industry benchmarksPortfolio Growth Summary & Growth Focused Investment Plans - Улправда
Is LENZ Therapeutics Inc. stock trading near support levels2025 Institutional Moves & Technical Pattern Recognition Alerts - ulpravda.ru
LENZ Therapeutics Stock Plummets 42% With 10-Day Losing Streak - Trefis
LENZ Therapeutics (NASDAQ:LENZ) Shares Up 5%What's Next? - MarketBeat
LENZ Therapeutics: Was That A Market Overreaction? (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
LENZ Therapeutics Stock 9-Day Losing Spree: Stock Falls 40% - Trefis
LENZ Therapeutics Currently Down Nine Consecutive Days, On Pace for Longest Losing Streak Since March 2022 -- Data Talk - 富途牛牛
8-Day Sell-Off Sends LENZ Therapeutics Stock Down 39% - Trefis
LENZ Therapeutics (NASDAQ:LENZ) Shares Gap UpHere's What Happened - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Sees Large Volume IncreaseShould You Buy? - MarketBeat
LENZ Therapeutics Responds to FDA Adverse Event Report - TipRanks
LENZ Therapeutics Addresses Adverse Event Report - TradingView — Track All Markets
Lenz Therapeutics (Nasdaq: LENZ) provides update on VIZZ safety data report - Stock Titan
ABBV Stock News: Lenz Therapeutics Faces Setback with FDA Report - GuruFocus
LENZ stock tumbles after retinal tear case surfaces in FDA database - Investing.com
LENZ stock plunges after adverse event report (LENZ:NASDAQ) - Seeking Alpha
Stempoint Capital LP Buys Shares of 183,912 LENZ Therapeutics, Inc. $LENZ - MarketBeat
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):